Skip to content

ATEC

NASDAQ

Alphatec Holdings Inc

Health Care
Health Care
Report Card

ATEC at a glance — five pillars scored 0–100 from real filed financials.

Value
Growth
Profitability
0
Health
0
Dividends
0

Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.

Key Metrics

Market Cap

$0.00

P/E

Forward P/E (est.)

ROE

Revenue Growth

EPS Growth

Profit Margin

FCF Yield

Debt / Equity

ROIC

-11.0%

Interest Coverage

Current Ratio

1.9x

Dividend Yield

Implied Growth (rev. DCF)

Rating Score

0/100

Business Overview
Research

Alphatec Holdings Inc (ATEC) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.

In its latest reported year it generated about $764.15M in revenue and posted a net loss of $143.36M.

Our model rates ATEC Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.

Revenue Growth
Research

4Y CAGR

33.1%

Revenue moved from $101.74M in 2017 to $764.15M in 2025, a 28.7% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.

Profitability
0/1 checks passedROIC above 10%

Gross Margin

69.6%

Operating Margin

-10.7%

Net Margin

-18.8%

ROE

Debt Analysis
Research
1/1 checks passedShort-term bills covered

Total Debt

$573.41M

Net Debt

$433.50M

Net Debt / EBITDA

Debt / Equity

Leverage: debt-to-equity is n/a, with a current ratio of 1.9x. Detailed balance-sheet leverage is limited for this name. It carries roughly $573.41M of total debt against $139.91M of cash.

Cash Flow Analysis
Research

Operating CF

$45.23M

Free Cash Flow

$2.78M

FCF Margin

0.4%

In the latest year Alphatec Holdings Inc produced about $45.23M of operating cash flow and $2.78M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.

Valuation Analysis
Research

P/E

P/S

P/B

EV / EBITDA

ATEC trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.

DCF Fair Value (Educational)

A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.

DCF fair value / share

$0.31

Current price

Starting FCF (latest 10-K)

$2.78M

Growth, years 1–5

4.0%

Fade to terminal, years 6–10

2.5%

Discount rate

9.0%

PV of 10-yr free cash flow$21.46M
PV of terminal value$26.21M
Estimated equity value$47.66M
Shares outstanding151M

Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.

Metrics vs. Sector Range

Where ATEC sits versus its Health Care sector peers in the S&P 500.

TTM P/E
Forward P/E
P/S ratio
Revenue growth
EPS growth
Gross margin
69.6%Average
Net margin
ROE

Bands show the middle half (25th–75th percentile) of the 42 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How ATEC stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.

In the Health Care sector (223 S&P 500 companies), ATEC ranks #71 of 223 by our overall rating.

P/E vs sector

median 26.2x

ROE vs sector

median 16.1%

Growth vs sector

median 7.5%

Sector rank

#71

of 223 by rating

CompanyP/ERev Gr.Rating
ATECThis stockNot rated
ACHCNot rated
ADUSNot rated
AHCONot rated
ALHCNot rated
ASSTNot rated
ASTHNot rated
ATRCNot rated
Health Care median26.2x7.5%0/100
Compare side by side

Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 223 S&P 500 names in the sector. Educational, not a recommendation.

Bull Case

The case for ATEC:

  • As an established S&P 500 member in Health Care, it brings scale and a long operating history.
Bear Case

The case against ATEC:

  • Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Research

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Investment Thesis
Research

On balance, the picture is mixed: Alphatec Holdings Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.

ATEC — frequently asked questions

Is ATEC a good stock to buy?

We don't give buy or sell advice. Review Alphatec Holdings Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.

Where does ATEC's data come from?

Live price data plus real fundamentals and 5-year financials pulled directly from Alphatec Holdings Inc's SEC filings — refreshed automatically, not hand-entered.

How is the 5-year projection for ATEC calculated?

It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.

Is this ATEC analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell ATEC. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.